Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1836-1840, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-774376
ABSTRACT
Immune-mediated hemocytopenia is a common cytopenic diseases without bone marrow hematopoietic abnormalities, the patient's quality of life is significantly reduced when first-line treatments are ineffective. Rapamycin, possesses a clear mechanism of targeting mTOR protein, can upregulate regulatory T cells and induces apoptosis of specific cells, by regulating the lymphocyte subsets, so as to treat various types of immune-mediated hemocytopenia with a certain therapeutic effect. In this reviews, the action mechanism and clinical application of rapamycin in immune thrombocytopenia(ITP), autoimmune hemolytic anemia(AIHA), acquired aplastic anemia and autoimmune lymphoproliferative syndrome(ALPS) etc. are summarized.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Calidad de Vida
/
Linfocitos T Reguladores
/
Sirolimus
/
Usos Terapéuticos
/
Serina-Treonina Quinasas TOR
/
Anemia Aplásica
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS